Last reviewed · How we verify
Other standard therapy for ADHD
Other standard therapy for ADHD is a Small molecule drug developed by Eli Lilly and Company. It is currently in Phase 3 development for Attention-Deficit/Hyperactivity Disorder (ADHD).
This represents a standard ADHD therapy from Eli Lilly, likely a stimulant or non-stimulant that increases dopamine and/or norepinephrine activity in the central nervous system to improve attention and reduce hyperactivity.
This represents a standard ADHD therapy from Eli Lilly, likely a stimulant or non-stimulant that increases dopamine and/or norepinephrine activity in the central nervous system to improve attention and reduce hyperactivity. Used for Attention-Deficit/Hyperactivity Disorder (ADHD).
At a glance
| Generic name | Other standard therapy for ADHD |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Therapeutic area | Neurology/Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Standard ADHD therapies typically work by enhancing catecholamine neurotransmission in brain regions responsible for attention, impulse control, and executive function. Stimulants (e.g., amphetamines, methylphenidate) increase dopamine and norepinephrine release, while non-stimulants (e.g., atomoxetine, guanfacine) may work through selective reuptake inhibition or alpha-2 agonism. Without a specific drug name or code, the exact mechanism cannot be definitively stated.
Approved indications
- Attention-Deficit/Hyperactivity Disorder (ADHD)
Common side effects
- Insomnia or sleep disturbance
- Decreased appetite
- Headache
- Nervousness or anxiety
- Increased heart rate or blood pressure
Key clinical trials
- REspiratory reHABilitation and PSYchiatric Comorbidities
- Interventions for English Language Learners At-Risk for ADHD (NA)
- Effects of Neurofeedback Training on Attentional Deficits in Patients With Acquired Brain Injury (NA)
- Mindfulness-Based ADHD Treatment for Children: a Feasibility Study (EARLY_PHASE1)
- Modified Comprehensive Behavioral Intervention for Tics (M_CBIT) (NA)
- Brain Tissue Integrity and Autonomic Function Alterations in Childhood OSA and ADHD, and After Adenotonsillectomy. (NA)
- Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study (NA)
- Improving Neurodevelopment in Adolescents With Congenital Heart Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Other standard therapy for ADHD CI brief — competitive landscape report
- Other standard therapy for ADHD updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI
Frequently asked questions about Other standard therapy for ADHD
What is Other standard therapy for ADHD?
How does Other standard therapy for ADHD work?
What is Other standard therapy for ADHD used for?
Who makes Other standard therapy for ADHD?
What development phase is Other standard therapy for ADHD in?
What are the side effects of Other standard therapy for ADHD?
Related
- Manufacturer: Eli Lilly and Company — full pipeline
- Therapeutic area: All drugs in Neurology/Psychiatry
- Indication: Drugs for Attention-Deficit/Hyperactivity Disorder (ADHD)
- Compare: Other standard therapy for ADHD vs similar drugs
- Pricing: Other standard therapy for ADHD cost, discount & access